Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Clazakizumab for Kidney Transplant Rejection
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug to treat people with antibody mediated rejection, which is a serious form of allograft rejection. Clazakizumab, an anti-IL6 monoclonal antibody, will be given monthly for six to twelve doses, and patients will have biopsies at 6 and 12 months to check for improvement.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.